Status:

COMPLETED

Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies

Lead Sponsor:

Singapore General Hospital

Collaborating Sponsors:

National Medical Research Council (NMRC), Singapore

Conditions:

Acute Myeloid Leukemia

Acute Lymphoblastic Leukemia

Eligibility:

All Genders

12-60 years

Phase:

PHASE1

PHASE2

Brief Summary

Cytokine-induced killer ( CIK ) cells have been shown by our lab to be cytolytic against both autologous and allogeneic acute myeloid leukemia ( AML ) cells. Large scale expansion of CIK cells has als...

Detailed Description

1. Patient inclusion criteria This trial includes only patients who have relapsed after an allogeneic transplant, who have either 1.1 No response to conventional DLI given for at least one dose, or 1....

Eligibility Criteria

Inclusion

  • This trial includes only patients who have relapsed after an allogeneic transplant, who have either:
  • No response to conventional DLI given for at least one dose, or
  • No possibility of access to large number of donor lymphocyte for repeated doses of DLI, This applies to cases of unrelated transplant or cord blood transplant
  • Patients who developed significant GVHD to conventional DLI, but had no other therapeutic option. In such cases the rationale is based on mice studies of mismatched CIK producing much less GVHD than mismatched unmanipulated splenocytes.
  • In view of the period taken to culture the cell to maturity, patient must have a life expectancy of more than one month. Interim measures eg chemotherapy or conventional DLI will be given during the interval so that ongoing treatment will not be compromised in any way.

Exclusion

  • Uncontrolled infection or significant bleeding
  • Unstable vital signs
  • Any degree of hypoxia requiring oxygen therapy.

Key Trial Info

Start Date :

August 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2012

Estimated Enrollment :

24 Patients enrolled

Trial Details

Trial ID

NCT00460694

Start Date

August 1 2006

End Date

December 1 2012

Last Update

February 10 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Singapore General Hospital

Singapore, Singapore, 169608